Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.2.1043

Hepatitis B Virus Gene C1653T Polymorphism Mutation and Hepatocellular Carcinoma Risk: an Updated Meta-analysis  

Shi, Hua-Ping (Zhejiang University Medical College)
Zhang, Jun (Laboratory Department, Sir Run Run Show Hospital of Zhejiang University Medical College)
Shang, Xue-Chai (Central Laboratory, Hang Zhou Red Cross Hospital)
Xie, Xin-You (Laboratory Department, Sir Run Run Show Hospital of Zhejiang University Medical College)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.2, 2013 , pp. 1043-1047 More about this Journal
Abstract
Although there have been many studies investigating possible associations between the C1653T mutation and risk of HCC, the results have been inconsistent. We conducted searches of the published literature in Pubmed and Embase databases up to January 2013. Seventeen studies with a total of 1,085 HCC cases and 1,365 healthy controls were retrieved. We found a significant association between the C1653T mutation and HCC risk (OR = 2.01, 95%CI= 1.49-2.70). In the subgroup analysis by ethnicity, a significant association was also found in Asians (OR = 2.07, 95%CI= 1.71-2.51). In subgroup analysis by HBV genotype, B and C were linked with development of HCC (B:OR = 2.21, 95%CI= 1.13-4.34; C:OR = 2.26, 95%CI= 1.61-3.16). However, no significant association was found between the C1653T mutation and HCC risk in HBeAg positive cases. In conclusion, this meta-analysis suggests that the C1653T mutation may be associated with susceptibility to HCC.
Keywords
HBV; C1653T mutation; HCC; meta-analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Brechot C (2004). Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology, 127, S56-61.   DOI   ScienceOn
2 Chan HL, Hui AY, Wong ML, et al (2004).Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, 1494-98.   DOI   ScienceOn
3 Cho EY, Choi CS, Cho JH, et al (2011).Association between Hepatitis B Virus X Gene Mutations and Clinical Status in Patients with Chronic Hepatitis B Infection. Gut Liver, 5, 70-76.   DOI   ScienceOn
4 Choi CS, Cho EY, Park R, et al (2009). X gene mutations in hepatitis B patients with cirrhosis, with and without hepatocellular carcinoma. J Med Virol, 81, 1721-5.   DOI   ScienceOn
5 Chu CM,(2002).Precore stop mutant in anti-HBe-positive phases of chronic hepatitis B virus infection. Am J Gastroenterol,97, 2138-9.
6 Cong YS, Yao YL, Yang WM, et al (1997). The hepatitis B virus X-associated protein, XAP3, is a protein kinase Cbinding protein. J Biol Chem, 272, 16482-9.   DOI   ScienceOn
7 Fang ZL, Sabin CA, Dong BQ, et al (2008). HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol, 103, 2254-62.   DOI   ScienceOn
8 Ferlay J, Shin HR, Bray F, et al (2010).Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-17.   DOI   ScienceOn
9 Guo X, Jin Y, Qian G, et al (2008). Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol, 49, 718-25.   DOI   ScienceOn
10 Ja KK, Hye YC, Jung ML, et al (2009). Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol, 81, 1002-8.   DOI   ScienceOn
11 Jang JW, Chun JY, Park YM, et al (2012). Mutational complex genotype of the hepatitis B virus X/precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci, 103, 296-304.   DOI   ScienceOn
12 Parkin DM, Bray FI, Devesa S, et al (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer, 37, S4-66.
13 Kumar V, Jayasuryan N, Kumar R (1996). A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function. ProcNatl Acad Sci USA, 93, 5647-52.   DOI
14 Lee H, Kim HT, Yun Y, et al (1998). Liver-specific enhancer II is the target for the p53-mediated inhibition of hepatitis B viral gene expression. J Biol Chem, 273, 19786-91.   DOI   ScienceOn
15 Liu S, Zhang H, Gu C, et al (2009). Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst, 101, 1066-82.   DOI   ScienceOn
16 Qu LS, Liu TT, Jin F, et al (2011). Combined pre-S deletion and core promoter mutations related to hepatocellular carcinoma: A nested case-control study in China. Hepatol Res, 41, 54-63.   DOI   ScienceOn
17 Sakamoto T, Tanaka Y, Orito E, et al (2006). Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. J Gen Virol, 87, 1873-82.   DOI   ScienceOn
18 Sakurai M, Sugauchi F, Tsai N, et al (2004). Genotype and phylogenetic characterization of hepatitis B virus among multi-ethnic cohort in Hawaii. World J Gastroenterol, 10, 2218-22.
19 Sherman M (2010). Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis, 30, 3-16.   DOI   ScienceOn
20 Shinkai N, Tanaka Y, Ito K, et al (2007). Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol, 45, 3191-7.   DOI   ScienceOn
21 Tangkijvanich P, Sa-Nguanmoo P, Mahachai V, et al (2010). A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatol Int, 4, 577-84.   DOI   ScienceOn
22 Sirma H, Giannini C, Poussin K, et al (1999). Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene, 18, 4848-9.   DOI   ScienceOn
23 Stemler M, Weimer T, Tu ZX, et al (1990). Mapping of B-cell epitopes of the human hepatitis B virus X protein. J Virol, 64, 2802-9.
24 Tanaka Y, Mukaide M, Orito E, et al (2006). Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol, 45, 646-53.   DOI   ScienceOn
25 Tatsukawa M, Takaki A, Shiraha H, et al (2011). Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer, 11, 458.   DOI
26 Wang Z, Tanaka Y, Huang Y, et al (2007). Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J Clin Microbiol, 45, 1491-6.   DOI   ScienceOn
27 Welschinger R, Kew MC, Viana R, et al (2010). T1653 mutation in the enhancer II region of the hepatitis B virus genome in southern African Blacks with hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 22, 541-5.   DOI
28 Yuan J, Zhou B, Tanaka Y, et al (2007). Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. J Clin Virol, 39, 87-93.   DOI   ScienceOn
29 Yuen MF, Tanaka Y, Shinhai N, et al (2008). Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C,specific mutations of enhancer II/core. Gut, 57, 98-102.
30 Zhang KY, Imazeki F, Fukai K, et al (2007). Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Sci, 98, 1921-9.   DOI   ScienceOn
31 Zhu Y, Jin Y, Guo X, et al (2010). Comparison study on the complete sequence of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev, 19, 2623-30.   DOI   ScienceOn